Archive | April, 2024

Confirmed Early-Stage Investors Attending RESI Europe in June

29 Apr

By Faith Patenaude, Investor Research Analyst, LSN

Faith

300 life science investors focused on clinical and preclinical companies are expected to attend RESI Europe. 100 are already confirmed! RESI Europe will be held in Barcelona in-person on June 17 and virtual June 18-19. Your members can meet more investors at RESI Europe than at any other partnering event in Europe. RESI Europe features a shark-tank like investor pitch challenge as well as 1-to-1 partnering. We invite tech hubs and their members to take advantage of special rates:

  • Super Early Bird Rate on RESI Registration for tech hub members who have raised less than $2 million USD.
  • Complimentary Ticket for a Second Attendee when purchasing a RESI Innovator’s Pitch Challenge (IPC) Package.
  • 50% Off RESI Sponsorship, enhancing your visibility and networking opportunities.
  • Discounted Subscription to the LSN Investor Database, providing access to over 10,000 investor contacts.

Contact Erika Wu E.WU@LifeScienceNation.com to discuss your eligibility and to access the appropriate discount codes.

RESI Europe stands as an exceptional platform for early-stage life science companies, providing unparalleled opportunities to engage and connect with a diverse array of European and global investors. The LSN investor research team has been diligently working to invite investors, including CVC, angel groups, family offices, venture capital funds, big pharma, and more. Each investor has undergone thorough vetting to ensure alignment with company profiles, guaranteeing a distinctive edge over other conferences and fostering high-caliber attendance. RESI’s partnering platform welcomes the opportunity for you to connect with investors with aligned interests and of best fit. RESI offers an outstanding chance for early-stage startups, service providers, and investors to cultivate meaningful connections and broaden their network within the life science sector.

Save up to €300 with our early bird rate – ending tomorrow, Friday May 17th. Sign up now and join the featured investors below.

RESI-Europe-Confirmed-Investors-4292024

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Life Science Nation Offers Tools to Prepare Global Partnering Campaigns

29 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) has delivered our Entrepreneurial Education fundraising and partnering curriculum to numerous life science tech hubs around the globe. LSN excels in crafting partnering-themed boot camps and webinars tailored to diverse needs, whether in-person, virtual, or hybrid. These programs are finely tuned to suit a cohort member’s development stages and product sets.

LSN has diverse experience and has worked closely with regional bio clusters such as California Life Sciences, incubators like Hong Kong Science and Technology Park, academic institutions like Georgia Tech, and regional accelerators like OBIO Toronto. These initiatives are specifically designed for life science cohorts around the globe on how to prepare and execute global roadshows and partner campaigns.

LSN also equips these cohorts with the necessary skills to effectively prepare for and implement best practices during in-person partnering events. Notable collaborations include the National Institute on Aging (NIA) under the NIH, the Brisbane Economic Development Association (BEDA) in their third consecutive year partnering with LSN, and an upcoming session sponsored by our Brazilian partner, ABIQUIF-Pharma Chemicals Industry Association. They collaborate with LSN to empower early-stage life science companies to learn the nuts and bolts of how to be successful in the global partnering landscape.

What truly sets LSN apart is our capacity to provide a comprehensive suite of products and services meticulously tailored to startups’ unique needs and challenges. Our startup cohorts’ clients seek Seed, Series A, or Series B funding. The LSN database offers a carefully curated list of current investors and licensing partners that can be matched to the startup’s stage of development and product. LSN has integrated the Salesforce.com CRM system to help startups organize and manage their interactions with these potential collaborators, along with an educational curriculum focused on the nuances of planning and executing a global roadshow. Additionally, we organize five RESI Investor conferences every few months, presenting invaluable opportunities to connect with key players and expand a company’s network outside their home region.

LSN’s offerings are strategically crafted to address the four primary challenges that often contribute to startups’ downfalls when entering the global life science partnering arena. By comprehensively understanding and tackling these challenges, we significantly enhance startups’ likelihood of success in this sector.

  • Understanding the Target Audience: Many early-stage companies lack clarity regarding their target audience. Venture capitalists (VCs) operate across different stages, each with distinct preferences and investment criteria. LSN equips startups with the knowledge to discern between early-stage, mid-stage, and late-stage VCs, enabling them to focus their efforts on engaging with investors aligned with their stage of development and product maturity. Our entrepreneurial education curriculum is dedicated to organizing and executing successful global roadshows.
  • Regional vs. Global Dynamics: LSN educates early-stage companies on navigating the global early-stage partner landscape, refining their narrative, and devising a coherent strategy for their global roadshow. Fundraising is inherently a numbers game, necessitating an international outlook to access an adequate pool of potential investors suited to their needs. Startups often overlook the global market potential for their technology assets, limiting their fundraising prospects. LSN guides startups in broadening their horizons and understanding the diverse opportunities beyond their regional boundaries.
  • Crafting Compelling Stories: Startups transitioning from academia often struggle to articulate their unique value proposition beyond generic problem/solution presentations. LSN emphasizes the importance of weaving personal narratives into pitch decks, highlighting the entrepreneur’s journey and the intrinsic qualities that make them investable. LSN addresses the prevailing trend of inadequately prepared pitch decks and offers guidance on crafting impactful narratives that resonate with investors.
  • Developing a Strategic Game Plan: Launching and executing a global fundraising campaign requires more than a problem/solution/addressable market pitch deck. We advocate for a holistic approach encompassing the fundamentals of sales, marketing, and business development. Startups must develop concise taglines, elevator pitches that capture investors’ attention, and personal narratives that underscore their credibility and potential as partners. Our training programs cover these essential aspects, equipping startups with the tools and strategies to navigate the competitive landscape effectively.

What Makes RESI Europe Stand Out

25 Apr

By Rikki Piccirillo, Marketing Manager, LSN

Rikki

We are excited to introduce RESI Barcelona 2024, where innovation converges with investment in Europe’s thriving life sciences ecosystem. Join us as we explore the dynamic opportunities highlighted by Greg Mannix, VP International Business Development at Life Science Nation.

RESI Barcelona 2024 combines in-person networking with a hybrid digital format, offering unparalleled access to over 300 early-stage companies. From the Innovators Pitch Challenge to engaging panels and workshops, RESI Barcelona promises a platform for startups to showcase cutting-edge technologies and connect with investors seeking the next big breakthrough.

English

Español

Register-now-button-new

RESI-Europe-2024-Banner-1100pxw

Exhibit at RESI Europe 

25 Apr

By Cameron Hurlburt, Director of Business Development, LSN

RESI returns to Europe at the Hilton Diagonal Mar Hotel in Barcelona. This conference is a hybrid format; in person on Monday, June 17 followed by two days of virtual partnering. Past in-person RESIs boasted a vibrant network of service providers, including CRO/CMOs, non-profits, suppliers, and professional services like law firms and banks. These service providers have played an essential role in the RESI ecosystem, and we are pleased to welcome them back with more offerings that include onsite and digital formats to promote their services and connect them with early-stage startups who need them.

DSC1819McDermott Will & Emery a global law firm exhibited at RESI South on March 25, 2024.

RESI’s unique value to its service providers is its dedication to early-stage companies in life science and healthcare. These startups have specific needs that make them ideal clients for a variety of providers. CRO/CMOs attend RESI to connect with preclinical therapeutics. Lab services with valuable R&D space, banks with life science-specific benefits, and law firms specializing in IP, term sheet negotiations, and more exhibit at RESI to connect with these founders who seek their services.

DSC9738-scaledCambridge Innovation Center exhibited at RESI Boston on June 5, 2023.

RESI exhibition includes a table for promotion and networking in the exhibit hall. Exhibitors also have their logo featured prominently on the RESI website, program guide, and onsite signage. The exhibitor package also includes a complimentary registration to participate in the partnering platform and attend all conference events. Interested in reaching a broad audience of early-stage entrepreneurs at RESI Europe Barcelona? Contact us to learn more!

RESI-Europe-2024-Banner-1100pxw

IPC Winner, Sanguina, Finds Connection at RESI South 

25 Apr

Interview with Erika Tyburski, CEO at Sanguina and Maria Thacker-Goethe, President & CEO at Georgia Bio By Caitlin Dolegowski, Marketing Manager, LSN

Erika TyburskiErika Tyburski
Maria Thacker-GoetheMaria Thacker-Goethe
CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Please introduce us to Sanguina and the company’s technology (and curious about the naming of your company).

Erika Tyburski (ET): Hi Caitlin. Sanguina means blood in Latin and is also derived from the English word sanguine- or relaxed. I co-founded Sanguina to make accessible tools to learn more about your health. We have a focus on blood health, and making tools that tell you something about blood. We are passionate about blood because it often changes first in response to a stress on the system- a cold, a deficiency, or a chronic disease. This is why blood testing is often used for diagnoses. Our first platform is called AnemoCheck for accessible and rapid anemia management. We recently received FDA-clearance on a home test for hemoglobin level determination and have a complementary smartphone application for determining likelihood of anemia based on the paleness of fingernails via a fingernail selfie.

CD: Maria, please introduce us to Georgia Bio. RESI South took place in Atlanta and there were many companies from Georgia represented RESI. Tell us about the life sciences ecosystem in Georgia and exciting companies emerging, such as Sanguina.

Maria Thacker-Goethe (MT): Georgia Bio is the life science association focused on enhancing the innovation environment in Georgia. Our main goals are advocating for favorable policies, linking members with funding and partners, and supporting workforce development in the state.

Sanguina is one of our standout companies, but it’s not alone. At the RESI conference, we also had Andson Biotech, Aruna Bio, and Emtherapro presenting to the 350 attendees. These companies represent our growing ecosystem. The life sciences sector in Georgia has seen significant growth, with a 20% increase in jobs since 2015, totaling 11,225, and generating a total economic impact of $50.2 billion, according to Biopharma Reporter. Georgia is emerging as a prominent life science hub.

CD: Maria, I know you have been to RESI before, Erika, this was your first conference. What are your experiences at RESI? What worked well for you both at RESI South?

ET: The event was very efficient. The networking platform enabled meetings to be made ahead of the event and the rapid 20-minute meetings allowed me to meet with many parties in a short amount of time. Talk about bang for buck! I found myself re-connecting with people that have seen me grow locally and meeting new people in the southeast region. I particularly enjoyed the pitch session and constructive questions given to me by the digital health panel.

MT: First off, I had a great experience at the RESI South event last month. My team and I had more than a dozen meetings with life science companies in the state. Although Georgia has all the seeds needed to grow a robust ecosystem, one of the big gaps is venture funding. That is why the state associations partnered with Life Science Nation. We are excited about our partnership and look forward to even stronger future events.

CD: Erika, what stage of fundraising is Sanguina in and what are your goals in 2024?

ET: We have closed our first priced round. Sanguina is fortunate enough to have completed our raise and we are looking to go to work and generate recurring revenue this year and next. Sanguina is primarily a B2B company, so I am aiming to onboard several new customers and execute contracts for custom versions of our products. I look forward to profitability, with my next round focused on growth.

CD: Congratulations on your second-place finish at RESI JPM’s Innovator’s Pitch Challenge (IPC)! What do you think was the key to your success and standing out at RESI JPM?

ET: I’ve pitched a lot. I’ve been given thousands of questions on Why? How? When? And I’ve learned in that time to be as honest as possible. I’m not afraid to say: “I’m working on that answer”, while also acknowledging that “I’ve faced many challenges, and know how to overcome” I think investors and experts in my industry appreciate my candor. Additionally, I learn by doing, so throughout the years, I haven’t been afraid to Just Do It. I’ve learned how to run clinical studies, how to execute a regulatory strategy, how to raise money, how to close that first customer.

CD: What advice would you like to give to fellow entrepreneurs about RESI conferences?

ET: Have confidence in what you do and know. Be humble and talk to everyone, you never know what one new connection will lead to. And use the networking platform, of course!

MT: My biggest piece of advice is to use the partnering system to meet investors. Over 200 investors attended RESI South, either in person or virtually, which the Southeast has never seen. These investors want to meet with you to get to know you and your business.


If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the RESI Europe 2024 IPC taking place June 17-19 with a 1-day in-person conference follow by 2-day virtual partnering at Hilton Diagonal Mar Barcelona in Barcelona, Catalonia, Spain. Applications are accepted on a rolling basis, so get your application submitted today!

RESI-Europe-2024-Banner-1100pxw

Register-now-button-new

Hot Investor Mandate: USA-Based Firm Invests in Therapeutics, Medical Devices, and Diagnostics Companies in US, Europe, Israel With Inaugural Life Sciences Fund

25 Apr

A merchant bank operates investment and advisory platforms while also being an active investor on a principal basis. The firm invests in a variety of industries including media & entertainment, renewable energy, digital assets, consumer, and life sciences. The firm recently had an initial close on their inaugural life sciences fund, and is actively seeking early-stage investment opportunities in Series A to C rounds. Initial check sizes will be between $3-7M with reserved follow-on investments. The firm focuses US-based companies, and will consider those based in Europe, Israel, and other geographies who are looking to expand operations or relocate to the US. 
 
Within life sciences, the firm will consider opportunities in therapeutics, medical devices, and diagnostics. The firm does not invest in digital health or healthcare IT-based solutions. The firm is opportunistic and will consider all types of novel modalities, technologies, and disease areas that address a high unmet medical need. While the firm does invest in early-stage companies, the firm will expect companies to have a lead asset and indication in place, demonstrating strong pre-clinical data and be close to IND filing. 
 
The firm seeks to work with companies with a committed, full-time management team in place. The firm typically does not lead investment rounds and prefers to syndicate with other likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

Hot Investor Mandate: Corporate Venture Fund Seeks Biotech Investment Opportunities in the US, China, and Europe, from Seed Stage to IPO

25 Apr

As a corporate venture arm of a leading global service provider, the fund is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The firm does not lead rounds and prefers companies with a lead investor in place.  Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The firm makes equity investments only and does not have an equity-for-service model.  

Separately from the corporate venture arm, the parent company also runs a program for which it collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the firm’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 
 
The firm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 
 
The firm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.